Hyperkalemia at admission is associated with in-hospital mortality and hypokalemia with cardiac arrest and new-onset atrial fibrillation in patients admitted with suspected acute coronary syndrome


In acute coronary syndrome ( ACS ), potassium imbalance at admission has been associated with in-hospital arrhythmias, cardiac arrest, and mortality.
However, several important presentation characteristics and subtype of ACS have not been considered.

Consecutive patients ( n = 32,955 ) admitted with suspected ACS between 2006 and 2011, registered in the Swedish Web-System for Enhancement and Development of Evidence-Based care in Heart Disease Evaluated According to Recommended Therapies ( SWEDEHEART ) and the Stockholm CREAtinine Measurements ( SCREAM ) project were included.

Associations between admission plasma potassium categories ( reference 3.5 less than 4.0 mmol/L ) and in-hospital outcomes including mortality, cardiac arrest, new-onset atrial fibrillation, and second- or third-degree atrioventricular block were assessed with logistic regression models.

U-shaped associations between admission potassium, mortality and cardiac arrest were observed. However, in fully adjusted models, only hyperkalemia ( 5.0 - less than 5.5 [ odds ratio, OR 1.83; 95% CI, 1.34-2.49 ] and greater than or equal to 5.5 mmol/L [ OR 2.27; 95% CI, 1.57-3.27 ] ) was associated with mortality, while only hypokalemia ( 3.0 - less than 3.5 [ OR 1.63; 95% CI, 1.21-2.19 ] and less than 3.0 mmol/L [ OR 2.72; 95% CI, 1.56-4.74 ] ) was associated with cardiac arrest.

Potassium less than 3.0 mmol/L ( OR 1.93; 95% CI, 1.00-3.76 ) was associated with new-onset atrial fibrillation.

After multivariable adjustment, no association was observed between potassium and second- or third-degree atrioventricular block.

Results were not modified by main diagnosis ( ACS subtype or non-ACS diagnosis ) or eGFR ( estimated glomerular filtration rate ).

In conclusion, hyperkalemia at admission is associated with in-hospital mortality and hypokalemia with cardiac arrest and new-onset atrial fibrillation in patients admitted with suspected acute coronary syndrome. ( Xagena )

Faxén J et al, Int J Cardiol 2018; Epub ahead of print

XagenaMedicine_2018



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved Darzalex Faspro ( Daratumumab and Hyaluronidase-fihj ), a...


The Pfizer-BioNTech COVID-19 vaccine contains a nucleoside-modified messenger RNA ( modRNA ) encoding the viral spike glycoprotein ( S ) of...


COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...


Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs...


Implantable cardioverter-defibrillator ( ICD ) use is associated with reduced short- and long-term mortality in patients with heart failure. Patients with...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Brukinsa ( Zanubrutinib ) capsules for...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


As the Zika virus continues to spread globally, new evidence has emerged about the virus's potentially detrimental effects on the...